INGELHEIM, Germany -- (BUSINESS WIRE) --
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto™ Respimat® is not indicated to treat asthma or acute deterioration of COPD.
COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease, affecting 210 million people worldwide.
1 It is a growing world health priority and is predicted to become the 3rd leading cause of death by 2030.
2 Patients are typically diagnosed when lung function is already significantly impaired.
3 COPD symptoms can negatively impact a patient’s ability to breathe especially when performing daily activities.
4 “A recent review of landmark studies indicates that loss of lung function is more accelerated in the early stages of COPD.
5 While no treatment slows the rate of decline, maintenance treatment with Stiolto™ Respimat® initiated at the time of diagnosis will improve lung function,” said Danny McBryan, MD, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc.
About Stiolto™ Respimat®
“Stiolto™ Respimat® produced greater lung function improvements in terms of FEV1 compared to tiotropium and olodaterol alone in patients with COPD across a range of severities (GOLD 2 to 4),”6,7,8 said Richard Casaburi, MD, PhD, professor and associate chief, Division of Respiratory and Critical Care Physiology and Medicine, Harbor-UCLA Medical Center. “As a clinician, I am pleased to have a new treatment option to offer my patients.”
Tiotropium is a long-acting anticholinergic and the active ingredient in Spiriva® Respimat® and Spiriva® HandiHaler®. Since its approval more than 10 years ago, Spiriva® has extensive clinical experience with over 40 million patient-years and more than 200 clinical trials. Spiriva® is the most prescribed COPD maintenance treatment worldwide.
Olodaterol, marketed as Striverdi® Respimat®, is a long-acting beta2-agonist that was specifically designed to complement the efficacy of Spiriva®. Olodaterol has a fast onset of action that has a clinically meaningful improvement in airflow five minutes after the first dose.
“The approval of Stiolto™ Respimat® in the U.S. marks an important milestone in our ongoing commitment to provide effective solutions for patients with COPD,” said Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Building on years of trusted experience with Spiriva®, Stiolto™ Respimat® provides even further benefits than Spiriva® alone and will offer a valuable new treatment option for patients and physicians. We look forward to the decision from the European regulatory authorities soon.”
The approval is based on data from the pivotal Phase III TONADO® 1&2 trials (NCT01431274/NCT01431287), which evaluated more than 5,000 COPD patients and showed Stiolto™ Respimat® provides statistically significant improvements in lung function over tiotropium and olodaterol alone.
6 The trials, part of the TOviTO® clinical trial programme involving more than 15,000 COPD patients worldwide, also showed Stiolto™ Respimat® has a safety profile similar to tiotropium or olodaterol alone.6
About the Respimat® Inhaler
Stiolto™ is administered via Respimat®, the propellant-free, platform inhaler for Boehringer Ingelheim’s respiratory therapies, including approved and investigational therapies. Respimat® is the only inhaler available that actively delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.9-15
For ‘Notes to Editors’ and ‘References’ please visit: https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/26_may_2015_copd.html
* Expected brand name in Europe is Spiolto™ Respimat®
View source version on businesswire.com: http://www.businesswire.com/news/home/20150526005570/en/
Media + PR
Dr Kristin Jakobs
Phone: +49 151 6894 7444
Fax: +49 (6132) 77 6601